Analyzing Janux Therapeutics (NASDAQ:JANX) & Roivant Sciences (NASDAQ:ROIV)

Janux Therapeutics (NASDAQ:JANX) and Roivant Sciences (NASDAQ:ROIV) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Analyst Ratings

This is a summary of current recommendations and price targets for Janux Therapeutics and Roivant Sciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2	2	10	1	2.67
Roivant Sciences	1	2	10	1	2.79

Janux Therapeutics currently has a consensus target price of $36.46, suggesting a potential upside of 100.89%. Roivant Sciences has a consensus target price of $45.64, suggesting a potential upside of 31.94%. Given Janux Therapeutics’ higher probable upside, equities research analysts plainly believe Janux Therapeutics is more favorable than Roivant Sciences.

Profitability

This table compares Janux Therapeutics and Roivant Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

Insider and Institutional Ownership

75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by insiders. Comparatively, 8.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Janux Therapeutics and Roivant Sciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$24.00 million	46.23	-$113.62 million	($1.64)	-11.07
Roivant Sciences	$7.53 million	3,317.20	-$299.77 million	($0.53)	-65.26

Janux Therapeutics has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Janux Therapeutics has a beta of 2.4, indicating that its stock price is 140% more volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500.

Summary

Janux Therapeutics beats Roivant Sciences on 9 of the 13 factors compared between the two stocks.

About Janux Therapeutics

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.